217 related articles for article (PubMed ID: 25354646)
1. Invited review: Drug development for tauopathies.
Grüninger F
Neuropathol Appl Neurobiol; 2015 Feb; 41(1):81-96. PubMed ID: 25354646
[TBL] [Abstract][Full Text] [Related]
2. An Overview on the Clinical Development of Tau-Based Therapeutics.
Medina M
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29641484
[TBL] [Abstract][Full Text] [Related]
3. Invited review: Animal models of tauopathies and their implications for research/translation into the clinic.
Dujardin S; Colin M; Buée L
Neuropathol Appl Neurobiol; 2015 Feb; 41(1):59-80. PubMed ID: 25428793
[TBL] [Abstract][Full Text] [Related]
4. Tau immunotherapy for Alzheimer's disease.
Pedersen JT; Sigurdsson EM
Trends Mol Med; 2015 Jun; 21(6):394-402. PubMed ID: 25846560
[TBL] [Abstract][Full Text] [Related]
5. Further understanding of tau phosphorylation: implications for therapy.
Medina M; Avila J
Expert Rev Neurother; 2015 Jan; 15(1):115-22. PubMed ID: 25555397
[TBL] [Abstract][Full Text] [Related]
6. Emerging Diagnostic and Therapeutic Strategies for Tauopathies.
Coughlin D; Irwin DJ
Curr Neurol Neurosci Rep; 2017 Sep; 17(9):72. PubMed ID: 28785992
[TBL] [Abstract][Full Text] [Related]
7. Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species.
Gerson JE; Castillo-Carranza DL; Kayed R
ACS Chem Neurosci; 2014 Sep; 5(9):752-69. PubMed ID: 25075869
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's Disease Drug Discovery--11th International Conference--Targeting Pathological Tau. 27-28 September 2010, Jersey City, NJ, USA.
Wolfe MS
IDrugs; 2010 Dec; 13(12):828-9. PubMed ID: 21154135
[TBL] [Abstract][Full Text] [Related]
9. A walk through tau therapeutic strategies.
Jadhav S; Avila J; Schöll M; Kovacs GG; Kövari E; Skrabana R; Evans LD; Kontsekova E; Malawska B; de Silva R; Buee L; Zilka N
Acta Neuropathol Commun; 2019 Feb; 7(1):22. PubMed ID: 30767766
[TBL] [Abstract][Full Text] [Related]
10. AADvac1, an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development.
Novak P; Zilka N; Zilkova M; Kovacech B; Skrabana R; Ondrus M; Fialova L; Kontsekova E; Otto M; Novak M
J Prev Alzheimers Dis; 2019; 6(1):63-69. PubMed ID: 30569088
[TBL] [Abstract][Full Text] [Related]
11. Disease-modifying strategies in primary tauopathies.
Rösler TW; Costa M; Höglinger GU
Neuropharmacology; 2020 May; 167():107842. PubMed ID: 31704274
[TBL] [Abstract][Full Text] [Related]
12. Tau immunotherapies: Lessons learned, current status and future considerations.
Sandusky-Beltran LA; Sigurdsson EM
Neuropharmacology; 2020 Sep; 175():108104. PubMed ID: 32360477
[TBL] [Abstract][Full Text] [Related]
13. Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies.
Clavaguera F; Grueninger F; Tolnay M
Neuropharmacology; 2014 Jan; 76 Pt A():9-15. PubMed ID: 24050961
[TBL] [Abstract][Full Text] [Related]
14. Tau-based therapies in neurodegeneration: opportunities and challenges.
Li C; Götz J
Nat Rev Drug Discov; 2017 Dec; 16(12):863-883. PubMed ID: 28983098
[TBL] [Abstract][Full Text] [Related]
15. Current Status of Clinical Trials on Tau Immunotherapies.
Ji C; Sigurdsson EM
Drugs; 2021 Jul; 81(10):1135-1152. PubMed ID: 34101156
[TBL] [Abstract][Full Text] [Related]
16. From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy.
Colin M; Dujardin S; Schraen-Maschke S; Meno-Tetang G; Duyckaerts C; Courade JP; Buée L
Acta Neuropathol; 2020 Jan; 139(1):3-25. PubMed ID: 31686182
[TBL] [Abstract][Full Text] [Related]
17. Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls.
Sigurdsson EM
J Alzheimers Dis; 2018; 64(s1):S555-S565. PubMed ID: 29865056
[TBL] [Abstract][Full Text] [Related]
18. Post-translational modifications of tau protein: implications for Alzheimer's disease.
Martin L; Latypova X; Terro F
Neurochem Int; 2011 Mar; 58(4):458-71. PubMed ID: 21215781
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer's disease: phenotypic approaches using disease models and the targeting of tau protein.
Lauretti E; Praticò D
Expert Opin Ther Targets; 2020 Apr; 24(4):319-330. PubMed ID: 32116063
[No Abstract] [Full Text] [Related]
20. Development of tau aggregation inhibitors for Alzheimer's disease.
Bulic B; Pickhardt M; Schmidt B; Mandelkow EM; Waldmann H; Mandelkow E
Angew Chem Int Ed Engl; 2009; 48(10):1740-52. PubMed ID: 19189357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
